Company Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines.
The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.
Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency.
It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease.
Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.
The company was incorporated in 2018 and is headquartered in Seattle, Washington.
| Country | United States |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 328 |
| CEO | Dr. Steven D. Harr M.D. |
Contact Details
Address: 188 East Blaine Street Seattle, Washington United States | |
| Website | https://www.sana.com |
Stock Details
| Ticker Symbol | SANA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001770121 |
| CUSIP Number | 799566104 |
| ISIN Number | US7995661045 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven D. Harr M.D. | President, Chief Executive Officer & Director |
| Susan Wyrick | Acting Chief Financial Officer, Treasurer, Principal Accounting Officer and Senior Vice President of Finance & Accounting |
| Bernard J. Cassidy J.D. | Executive Vice President, General Counsel & Corporate Secretary |
| Dr. Dhavalkumar D. Patel M.D., Ph.D. | Executive Vice President & Chief Scientific Officer |
| Dr. Sonja Schrepfer M.D., Ph.D. | Senior Vice President & Head of Hypoimmune Platform |
| Snehal Patel | Senior Vice President & Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2024 | 3/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | 8-K | Current Report |
| Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 15, 2024 | 3 | Filing |